Trial Profile
Phase II trial of ATI 9242 in patients with schizophrenia
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 05 May 2015
Price :
$35
*
At a glance
- Drugs ATI 9242 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Braeburn Pharmaceuticals
- 05 May 2015 New trial record
- 01 May 2015 Braeburn Pharmaceuticals has licensed development and commercialisation rights to ATI-9242 from Oncothyreon and is planning to develop a long-acting formulation and to initiate a phase II trial in 2015, according to a media release.